Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial will investigate the use of the novel oral IRAK-4 inhibitor CA-4948 in combination with pembrolizumab therapy following stereotactic radiosurgery in patients with melanoma brain metastases (MBM). The investigators hypothesize that the addition of CA-4948 will reduce the rate of distant intracranial failure and reduce the need for subsequent radiation therapy. The investigators also propose that it will have a significant reduction in radiation necrosis and improve patient-reported symptoms and quality of life. This trial represents the first time an oral IRAK-4 inhibitor has been used in combination with aPD1 therapy in MBM and will yield valuable insight into its synergistic potential both in MBM and additional sites of metastases.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05669352
Study type Interventional
Source University of Florida
Contact Priya Gurjar
Phone 352-273-6772
Email PMO@cancer.ufl.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date July 2024
Completion date August 2027